Parataxis Korea, Inc. (KOSDAQ:288330)
416.00
-13.00 (-3.03%)
At close: Apr 7, 2026
Parataxis Korea Revenue
Parataxis Korea had revenue of 875.56M KRW in the quarter ending June 30, 2026. This brings the company's revenue in the last twelve months to 1.59B, up 14,151.50% year-over-year. In the year 2025, Parataxis Korea had annual revenue of 9.00M with 313.21% growth.
Revenue (ttm)
1.59B
Revenue Growth
+14,151.50%
P/S Ratio
27.70
Revenue / Employee
75.86M
Employees
21
Market Cap
44.13B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 9.00M | 6.82M | 313.21% |
| Dec 31, 2024 | 2.18M | -97.82M | -97.82% |
| Dec 31, 2023 | 100.00M | -2.92B | -96.69% |
| Dec 31, 2022 | 3.02B | 1.10B | 57.15% |
| Dec 31, 2021 | 1.92B | -4.42B | -69.65% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| KoBioLabs | 75.41B |
| J2KBIO | 43.90B |
| Eutilex.Co.,Ltd | 7.71B |
| QuadMedicine | 7.14B |
| TegoScience | 6.18B |
| HLB Pep | 5.54B |
| Kainos Medicine | 1.40B |
| Quratis | 1.10B |